Lineage Cell Therapeutics (LCTX) Gains from Investment Securities (2010 - 2026)

Lineage Cell Therapeutics has reported Gains from Investment Securities for 17 years, with the latest figure at $15000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities changed 0.0% year-over-year to $15000.0; the trailing twelve-month figure through Mar 2026 stood at $15000.0 (down 61.54% YoY), and the FY2025 full-year result was $23.2 million, up 130.25% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $15000.0, up from $1000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $35.2 million in Q2 2025, with the low at $1000.0 in Q4 2023.
• Historically, Gains from Investment Securities has averaged $7.3 million across 5 years, with a median of $649500.0 in 2022.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities jumped 20793.1% — and 2023, when it tumbled 99.98%.
• Lineage Cell Therapeutics' Gains from Investment Securities stood at $6.0 million in 2022, then plunged by 99.98% to $1000.0 in 2023, then surged by 50300.0% to $504000.0 in 2024, then sank by 99.8% to $1000.0 in 2025, then surged by 1400.0% to $15000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $15000.0 (Q1 2026), $1000.0 (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.